Enovis Corporation

What they do

Enovis manufactures and distributes medical devices used for reconstructive surgery, rehabilitation, pain management and physical therapy. It reports through two segments: Prevention & Recovery (bracing, hot/cold therapy, bone growth stimulators, vascular therapy and compression, electrical stimulators) and Reconstructive (implants, instrumentation and enabling technology for hip, knee, shoulder, elbow, foot, ankle and finger procedures). Products reach customers through independent distributors and direct salespeople, with manufacturing facilities in North America, Europe, Africa and Asia.

Revenue drivers

• Reconstructive segment — Sells implants, instrumentation and enabling technologies for joint replacement, limb reconstruction and foot & ankle procedures, including primary and revision cases; management described it in the 10-K as the innovation market-leader in the surgical implant business.
• Prevention & Recovery segment — Sells non-surgical orthopedic products such as bracing, hot and cold therapy, bone growth stimulators, vascular therapy and compression garments, and physical therapy stimulators to clinicians and at-home users.
• Acquisitions — Enovis completed seven transactions in 2025 for $36.9 million total consideration — three in P&R and four in Recon (three distributors, two businesses, two IP purchases) — adding distribution partners in Europe and complementary product technology.
• Divestitures reshaping the portfolio — The Dr Comfort Footcare Solutions U.S. operations in P&R were sold to Promus Equity Partners on October 7, 2025 for up to $60 million in cash ($45 million upfront, up to $15 million on milestones).

Recent performance

Second-quarter 2026 net sales were $583 million, up 3% reported and 5% organic year over year. Recon sales grew 8% reported and 6% organic, while P&R declined 1% reported but grew 3% organic. Enovis reported a second-quarter net loss of $1 million, or 0.2% of sales, and adjusted EBITDA of $104 million (17.9% of sales). Adjusted net earnings were $0.90 per diluted share against a net loss of $0.02 per share.

Strategy

Management describes a more focused organization and a portfolio "meaningfully reshaped over the past several years," citing improving commercial execution and an innovation pipeline. Enovis complements organic growth with acquisitions and uses its EGX business system for continuous improvement. The Dr Comfort divestiture and the small 2025 acquisitions continued the pruning and bolt-on approach. The company reaffirmed 2026 guidance for revenue, adjusted EBITDA, adjusted EPS and free cash flow conversion, and its CEO noted agility in navigating dynamic end markets while acknowledging more work is needed for consistent growth.

Risks

• Acquisition integration — The 10-K states that if the Lima Acquisition is not successfully integrated into existing operations, business and financial results may be adversely affected.
• Debt and leverage — The company carries long-term debt of $1.25 billion against $12.6 million of cash as of July 3, 2026, and the 10-K lists restrictions in its debt agreements that may limit operating flexibility.
• Goodwill and intangible impairment — The 10-K risk factors flag impairment risk from a sustained decline in operating performance at one or more business units or in the market price of the common stock.
• Distribution reliance — Enovis depends on a variety of distribution methods, including independent distributors, to market and sell its medical device products, a reliance the 10-K identifies as a risk factor.

Outlook

Enovis reaffirmed full-year 2026 revenue of $2.31–2.37 billion, incorporating 4–6% organic growth, based on current exchange rates. Adjusted EBITDA is expected at $425–435 million and full-year adjusted EPS at $3.52–$3.73. Full-year free cash flow conversion is expected to be 25% or higher. Management anticipates a more dynamic macroeconomic environment in the second half.